Our proprietary TGen technology allows us to formulate a broad range of therapeutics – from sensitive antibodies and growth factors to molecules typically incompatible with solvents used to formulate polymeric delivery systems – into extended release formulations precisely tailored to meet even the most demanding delivery profiles. Using formats from microspheres to fibers, we can design the right extended release system for nearly any compartment in the body, from eyes and nerve sheaths to joints and skin.

TissueGen is advancing a pipeline of novel, extended release formulations of generic drugs for the treatment of eye, nerve, and joint injuries and diseases toward clinical development.

Stay tuned for updates.

APPLICATIONS

TissueGen is advancing a pipeline of novel, extended release formulations of generic drugs

for the treatment of eye, nerve, and joint injuries and diseases toward clinical development.

Stay tuned for updates.

ADVANCED 

DRUG DELIVERY

Our proprietary TGEM 

technology allows us to formulate a broad range of 

therapeutics – from sensitive antibodies and growth factors to
molecules typically incompatible with solvents used to formulate 
polymeric delivery systems – into extended release formulations
precisely tailored to meet even the most demanding delivery
 profiles. Using formats from microspheres to fibers, we can 
design the right extended release system for nearly any 
compartment in the body, from eyes and nerve 
sheaths to joints and skin.

DEVELOPMENT

 
 

NERVE

REGENERATION

Our proprietary fibers can be tailored to deliver sensitive growth factors along a precise gradient for an extended period of time. We are developing applications of this technology for the repair of severed peripheral nerves without the need for harvesting nerves from elsewhere in the patient’s body. 

NERVE

REGENERATION

Our proprietary fibers can be 

tailored to deliver sensitive growth factors

along a precise gradient for an extended period
of time. We are developing applications of this technology 
for the repair of severed peripheral nerves without 
the need for harvesting nerves from elsewhere 

in the patient’s body. 

 

Our strong, pliable fibers can be woven, knitted, or braided to create biomimetic three- dimensional structures with unrivaled drug delivery capabilities for accelerating healing of repaired hernias and soft tissue injuries involving ligaments and tendons.

 

TISSUE

ENGINEERING

Our strong, pliable fibers can be

woven, knitted, or braided to create

biomimetic three-dimensional structures with unrivaled
drug delivery capabilities for accelerating healing of repaired
hernias and soft tissue injuries involving
ligaments and tendons.
 

PATENTS

COUNTRIES

Below you will find a list of our issued patents and pending applications.

DRUG RELEASING BIODEGRADABLE

FIBER IMPLANT:

CANADA

2379909 - Granted

CHINA

00814022.7 - Granted

EUROPEAN PATENT CONVENTION

00952592.4 - Pending

JAPAN

5383757 - Granted

USA

6,858,222 - Granted

7,514,095 - Granted

6,596,296 - Granted

DRUG RELEASING BIODEGRADABLE

FIBER FOR THE DELIVERY OF THERAPEUTICS:

AUSTRALIA

2004237770 - Granted

CANADA

2523620 - Granted

CHINA

200480018348.8- Granted

EUROPE

1620038 - Granted

FRANCE

1620038 - Granted

GERMANY

1620038 - Granted

GREAT BRITAIN

1620038 - Granted

ITALY

1620038 - Granted

JAPAN

2006-513446 - Granted

2012-046180 - Granted

SPAIN

1620038 - Granted

USA

2006-513446 - Granted

2012-046180 - Granted

CHEMICAL GRADIENTS:

AUSTRALIA

2014219149 - Granted

CANADA

2,901,919 - Pending

CHINA

201480017217.1 - Pending

201710861068.2 - Pending

EUROPEAN PATENT CONVENTION

14709037.7 - Pending

JAPAN

2015-558197 - Pending

USA

14/768,820 - Pending

SELF EXPANDING MEDICAL DEVICE:

AUSTRALIA

2009283913 - Granted

CANADA

2734493 - Granted

CHINA

ZL200980137732- Granted

EUROPEAN PATENT CONVENTION

2326292 - Granted

FRANCE

2326292 - Granted

GERMANY

2326292 - Granted

GREAT BRITAIN

2326292 - Granted

INDIA

1933/DELNP/2011 - Pending

ITALY

502016000124521 - Granted

JAPAN

5713900 - Granted

SPAIN

2326292 - Granted

USA

8,672,996 - Granted

DRUG ELUTING SELF RETAIN SUTURES

AND METHODS RELATING THERETO:

AUSTRALIA

2011323299 - Granted

BRAZIL

BR112013011090-2 - Pending

CANADA

2816326 - Pending

CHINA

201180063975.3- Pending

EUROPEAN PATENT CONVENTION

11838842.0 - Pending

INDIA

3929/DELNP/2013 - Pending

JAPAN

2013-537843 - Pending

KOREA

2013/7014209 - Pending

MEXICO

MX/A/2013/005072 - Pending

NEW ZEALAND

610341 - Pending

RUSSIA

2013125475- Granted

SOUTH AFRICA

2013/04011 - Pending

USA

13/883066 - Pending

DEVICE FOR INDUCTION OF CELLULAR ACTIVITY:

AUSTRALIA

2015346044 - Pending

CANADA

2967650 - Pending

CHINA

201580073483.0 - Pending

EUROPEAN PATENT CONVENTION

15859470.5- Pending

INDIA

201717020515 - Pending

JAPAN

2017-525948 - Pending

USA

15/524,211 - Pending

METHODS AND COMPOSITIONS FOR MAINTAINING THE CONFIRMATIONS AND STRUCTURAL INTEGRITY OF BIOMOLECULES:

PATENT COOPERATION TREATY

PCT/US2017/042666- Pending

TissueGen, Inc.
2110 Research Row, Suite 330
Dallas, Texas 75235
+ 1.214.351.1922
info@tissuegen.com

  • Facebook
  • Twitter
  • Instagram

Site produced by Lovage Inc.